Advanced Oncotherapy PLC Investor Day Update (4026C)

TIDMAVO

RNS Number : 4026C

Advanced Oncotherapy PLC

19 October 2020

19 October 2020

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Investor Day Update

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, will today hold its Investor Day presentation at 14:00 BST. The Company will be hosting a presentation accessible to all through the digital online platform Investor Meet Company, via the following link: https://www.investormeetcompany.com/advanced-oncotherapy-plc/register-investor .

A recording of the presentation and a copy of the slide deck will be available on the Investor Meet Company platform shortly after the live presentation.

Today's Investor Day presentation will be held by the Company's Senior Management team, where they will provide (i) an update on the current dynamics within the proton therapy market, (ii) an overview of the technical and potential treatment benefits of Advanced Oncotherapy's proprietary LIGHT proton therapy system, and (iii) a review of the Company's recent progress, proposed business model and outlook. In particular:

-- The Company will discuss the broader market potential for proton therapy and outline how its LIGHT system could accelerate the adoption of proton therapy as a treatment modality for a number of different cancer indications.

-- The Company will discuss how the LIGHT system can potentially be adapted for FLASH delivery of protons, an emerging mode of proton therapy treatment that utilises ultra-high dose rates - potentially providing the same treatment effects of typical proton radiation sessions - but in a fraction of the time. This may not only dramatically increase the rate at which patients can be treated, but also the types of tumour that are considered suitable for proton therapy. The potential of the LIGHT system to deliver mini-beams will also be outlined as well as how this could allow treatments to be highly sculpted to address irregular shaped tumours.

-- The Company expects to have a fully operational LIGHT system, at Daresbury, with a beam energy suitable to support patient treatment during 2021. Actual treatment of patients, which is expected to occur shortly after this LIGHT machine is fully operational, remains dependent on the Company's clinical partner, University Hospital Birmingham.

-- The Company will discuss how the modularity of the LIGHT system is the foundation of a differentiated and profitable business model: the opportunity to use the LIGHT system as collateral in financing transactions is a unique selling point in proton therapy and is expected to (i) support the funding for manufacturing new machines, (ii) facilitate the acquisition of the technology by customers, (iii) accelerate the pipeline of commercial orders and (iv) create a sustainable and diversified source of cash-flows.

-- Following the Company's successful partnership efforts to date, the Board of Advanced Oncotherapy expect that further commercial collaborations and purchase orders will be signed in 2021 given the Company's strong pipeline of global opportunities.

-- Recent expansion of the Company's partnership with the Cleveland Clinic, which will now be able to refer cancer patients from its London facility to Advanced Oncotherapy's London Clinic site in Harley Street, is expected to result in more patients being treated at the London Clinic site, from which the Company would receive a share of the profits.

Nicolas Serandour, CEO of Advanced Oncotherapy, said:

"At today's presentation, we will reaffirm our view from the interim results that, although there have been headwinds caused as a result of Covid-19 pandemic during 2020, the Company has made strong progress and now has all the key high-precision components of the accelerator in place at Daresbury. 2021 is set to be an exciting year for the Company as we expect to have a fully operational LIGHT system with a 230MeV beam, which is the beam energy needed to treat patients. We also expect to sign further commercial agreements for new machines as we progress our robust pipeline of opportunities."

- ENDS -

 
 Advanced Oncotherapy plc                                                  www.avoplc.com 
 Dr. Michael Sinclair, Executive Chairman                       Tel: [phone] 
 Nicolas Serandour, CEO 
 
 Allenby Capital Limited (Nomad and Joint Broker) 
 Nick Athanas / Liz Kirchner (Corporate Finance)                Tel: [phone] 
  Amrit Nahal / Matt Butlin (Sales & Broking) 
 
 SI Capital Ltd (Joint Broker) 
 Nick Emerson                                                   Tel: [phone] 
 Jon Levinson                                                   Tel: [phone] 
 
 FTI Consulting (Financial PR & IR)                 [e-mail] 
 Simon Conway / Rob Winder                                      Tel: [phone] 
 

Notes for Editors

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDEAEEPFEPEFAA

(END) Dow Jones Newswires

October 19, 2020 02:00 ET (06:00 GMT)